Plasmodium heme-dependent endoperoxide activation mechanism

The term "Plasmodium species endoperoxide activation" refers not to a single molecular target but rather to a **biochemical process** by which certain antimalarial drugs—most notably artemisinin and its derivatives—are activated inside malaria parasites. This process is **heme-dependent**: as the Plasmodium parasite digests host hemoglobin during its intraerythrocytic stages, it releases large amounts of heme. The iron within this heme catalyzes the cleavage of the drug’s characteristic endoperoxide bridge, generating highly reactive free radicals. These radicals then alkylate multiple targets within the parasite—including proteins and heme itself—leading to widespread cellular damage and ultimately death of the organism[2][3][4]. This mechanism explains both artemisinin's potency against late-stage parasites with high levels of released heme, as well as its selectivity for infected cells over uninfected erythrocytes[3]. Because this entry describes an **activation mechanism** rather than a discrete protein or receptor target, it should not be considered a canonical therapeutic target. Key points: > The mechanism involves two steps. Intra-parasitic iron catalyses cleavage of the drug’s endoperoxide bridge generating free radicals; these then form covalent bonds with malarial proteins.[2] > Artemisinin activation requires heme—not just ferrous iron—and is most potent against late-stage parasites due to high levels from hemoglobin digestion.[3] > By alkylating heme, these drugs disrupt iron homeostasis in Plasmodium.[4]

Other names

Plasmodium endoperoxide activationHeme-mediated artemisinin activation in PlasmodiumIron-catalyzed endoperoxide cleavage in malaria parasites

Heme-dependent cleavage of the drug’s endoperoxide bridge generates reactive free radicals that alkylate parasite proteins and heme, disrupting essential biological processes[2][3][4].